Nectar Lifesciences (NSE:NECLIFE) Cash-to-Debt : 0.05 (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Nectar Lifesciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nectar Lifesciences's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.05.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Nectar Lifesciences couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Nectar Lifesciences's Cash-to-Debt or its related term are showing as below:

NSE:NECLIFE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.05
Current: 0.05

During the past 13 years, Nectar Lifesciences's highest Cash to Debt Ratio was 0.05. The lowest was 0.01. And the median was 0.03.

NSE:NECLIFE's Cash-to-Debt is ranked worse than
90.22% of 1053 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs NSE:NECLIFE: 0.05

Nectar Lifesciences Cash-to-Debt Historical Data

The historical data trend for Nectar Lifesciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nectar Lifesciences Cash-to-Debt Chart

Nectar Lifesciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

0.03

0.02

0.05

Nectar Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.02	N/A	0.05	N/A	0.05

Competitive Comparison of Nectar Lifesciences's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nectar Lifesciences's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's Cash-to-Debt falls into.

Nectar Lifesciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Nectar Lifesciences's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	295.212	/	(4952.276	+	1403.087)
	=	0.05

Nectar Lifesciences's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	295.212	/	(4952.276	+	1403.087)
	=	0.05

Nectar Lifesciences (NSE:NECLIFE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Nectar Lifesciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nectar Lifesciences (NSE:NECLIFE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (NSE:NECLIFE) » Definitions » Cash-to-Debt

Traded in Other Exchanges

532649:India

Address

SCO 38-39, Sector 9d, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009

Website

https://www.neclife.com

Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences (NSE:NECLIFE) Headlines

No Headlines